PDSB News and Press, PDS Biotechnology Corporation From 11/14/22

PDS Biotechnology Corporation (PDSB) Q3 2022 Results Conference Call November 14, 2022 08:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matt Hil...

PDS Biotechnology ( NASDAQ: PDSB ) reported updated data from an ongoing phase 2 trial of PDS0101 in combination with chemoradiotherapy to treat patients with cervical cancer. The company said 9 out of 9 patients treated with PDS0101 and standard-of-care chem...

PDS Biotechnology press release ( NASDAQ: PDSB ): Q3 GAAP EPS of -$0.26 beats by $0.02 . Matthew Hill, Chief Financial Officer of PDS Biotech, stated, “We are excited about the progress we have made in our development programs, and we have strengthened the balan...

Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The University of Texas MD Anderson Cancer Center (IMMUNOCERV) and The National Cancer Institute at SITC 2022 Announced successful end-of-Phase 2 meeting with FDA for VERSATILE-002, allowi...

In the trial studying the combination of PDS0101 with standard-of-care chemoradiotherapy: 100% (9/9) showed clinical response (>60% tumor shrinkage at mid-point evaluation) 89% (8/9) had no evidence of disease (complete response) on day 170 Data Presented ...

PDS Biotechnology ( NASDAQ: PDSB ) is scheduled to announce Q3 earnings results on Monday, November 14th, before market open. The consensus EPS Estimate is -$0.28 Over the last 3 months, EPS estimates have seen 5 upward revisions and 0 downward. For further d...

Patients with high-risk, locally advanced cervical cancer on IMMUNOCERV demonstrated increased tumor-infiltrating polyfunctional CD8+ (killer) T cells, and 1-year overall survival of 100% Data from study across several checkpoint inhibitor refractory HPV-positive cancers demonst...

FLORHAM PARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will release financial res...

Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study Combination shows potential to achieve oncologists’ goals of improved clinical outcomes with improved quality of life and sur...

FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Chief Medical Officer, Dr. Lauren V. W...